Medical Advocates
HIV/HBV Coinfection
 
Drugs
 
Adefovir 
 Atazanavir 
Darunavir
Efavirenz
 Entecavir
 Lamivudine
Maraviroc
Nelfinavir		 Pegylated IFN-alpha2a
Sorafenib
Raltegravir
Rilpivirine
 Tenofovir
Tenofovir/Emtricitabine
ARVs: General|
 


 
HIV/HBV Main Page Main New/Newsworthy  Home Page
Last Update:  April 26, 2012  
 Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader
Atazanavir
 
     Journal Papers, Abstracts, and Commentaries
 
 
A WEEK-IN-REVIEW FEATURED REPORT
Short-Term Effect of Ritonavir-Boosted Atazanavir in Hepatitis B and/or C Co-infected,
Treatment-Experienced HIV Patients.
 Pérez-Elías MJ, Gatell JM, Flores J, et al
HIV Clin Trials. 2009 Jul-Aug;10(4):269-75|
 Abstract

Liver toxicity of antiretroviral combinations including atazanavir/ritonavir in patients
co-infected with HIV and hepatitis viruses: impact of pre-existing liver fibrosis.
 Pineda JA, Santos J, Rivero A, et al
J Antimicrob Chemother. 2008 Feb 14
Abstract

     Conference Reports, Abstracts, and Posters
 
Atazanavir is safe and efficacious in HBV and HCV co-infected patients: results of AI424138 (CASTLE)
 Absalon J, Thal G, Thiry A, Yang R, et al
(Ninth International Congress on Drug Therapy in HIV Infection)
 Abstract

Hepatic effects of atazanavir plus ritonavir (ATV/r)-based combinations in patients with
hepatitis virus coinfection: relationship with pre-existing liver damage
 Abdel-Kader L, Santos J, Rivero A, et al
 (4th IAS Conference)
 Abstract
Darunavir
 

     Journal Papers, Abstracts, and Commentaries

  Safety, Tolerability, and Efficacy of Darunavir (TMC114) with Low-Dose Ritonavir in
Treatment-Experienced, Hepatitis B or C Co-infected Patients in POWER 1 and 3.
Rachlis A, Clotet B, Baxter J, et al
HIV Clin Trials. 2007 Jul-Aug;8(4):213-20.
Abstract
Efavirenz
 

     Journal Papers, Abstracts, and Commentaries

 
A WEEK-IN-REVIEW FEATURED REPORT
Influence of liver fibrosis stage on plasma levels of efavirenz in HIV-infected patients with chronic
hepatitis B or C.
 Meynard JL, Lacombe K, Poirier JM,  et al
 J Antimicrob Chemother. 2009 Jan 23.
 Abstract

Efavirenz-therapy in HIV-patients with Underlying Liver Disease: Importance of Continuous TDM
of EFV.
 Katsounas A, Frank A, Klinker H, Langmann P. 
Eur J Med Res. 2007 Aug 16;12(8):331-6
Abstract
Entecavir
 

     News

 
PDF LETTER
 Dear Provider Letter Recommending that Entecavir Not Be Used for HIV/HBV
Coinfected Patients 
BMS
August 16, 2007
Letter

Entecavir should not be used for the treatment of HBV infection without
concomitant treatment for HIV for HBV/HIV co-infected patients.
US FDA
May 01, 2007
 News Release
 
     Journal Papers, Abstracts, and Commentaries
 
 
Managing hepatitis B/HIV co-infected: adding entecavir to truvada (tenofovir/emtricitabine)
experienced patients.
Ratcliffe L, Beadsworth MB, Pennell A,  et al
AIDS. 2011 Feb 22.
 Abstract

A case of HIV coinfected with hepatitis B virus treated by entecavir.
 Yamada A, Sako A, Nishimura S, et al  
 Nippon Shokakibyo Gakkai Zasshi. 2009 Dec;106(12):1758-63
 Abstract

Efficacy and safety of entecavir for chronic HBV in HIV/HBV coinfected patients receiving lamivudine
as part of antiretroviral therapy.
 Pessôa MG, Gazzard B, Huang AK, et al 
AIDS. 2008 Sep 12;22(14):1779-87.
 Abstract
 
A case of HIV co-infected with hepatitis B virus precore/core deletion mutant treated by entecavir
 Fukushima K, Ueno Y, Inoue J, et al 
Hepatol Res. 2008 May 20
 Abstract
 
Lack of an Effect of HIV Co-Infection on the Pharmacokinetics of Entecavir in HBV
Infected Patients.
 Zhu M, Bifano M, Xu X, et al
Antimicrob Agents Chemother. 2008 Apr 7
 Abstract

The anti-HIV antiviral activity of entecavir: The loss of a trusted friend?
 Sasadeusz J. 
J Hepatol. 2007 Oct 1;
 Abstract

     Conference Reports, Abstracts, and Posters

 
Use of entecavir in HIV and hepatitis B virus (HBV) co-infected individuals
 V. Harding, C. Bell, J. Underwood
(XVII International AIDS Conference)
 Abstract
 
Antiviral activity of entecavir against various HIV-1 clades, drug resistant mutants and HIV-2 in
human lymphocytes
 M.A. Detorio, K.L. Rapp, M.R. Cristiano, et al
 (XVII International AIDS Conference)
 Abstract
 
The Anti-HIV Activity of Entecavir: Serum HIV RNA Decreases and Selection of the M184V
Mutation Occurs in both ART-naïve and -experienced HIV/HBV-co-infected Individuals
 J Audsley, J Sasadeusz, A Mijch, et al
 (15 CROI)
 Abstract

The Anti-Hepatitis B Drug Entecavir Inhibits HIV-1 Replication and Selects HIV-1 Variants
Resistant to Antiretroviral Drugs
M McMahon, B Jilek, T Brennan, et al
(14 CROI)
 Abstract

Week-48 Resistance Surveillance of HIV/HBV-co-infected Patients Treated with Entecavir in
Study AI463038
 R Colonno, R Rose, C Baldick
 (13 CROI)
Abstract
 
Entecavir in HIV/HBV-co-infected Patients: Safety and Efficacy in a Phase II Study (ETV-038)
 W Pessoa, B Gazzard, A Huang, et al
 (13 CROI)
 Abstract
Maraviroc
 
     Journal Papers, Abstracts, and Commentaries
 
 
Safety Profile of Maraviroc in Patients Coinfected With HIV-1 and Hepatitis B or C Included in the
Maraviroc Expanded Access Program.
Lazzarin A, Than S, Valluri SR, et al
HIV Clin Trials. 2012 Mar-Apr;13(2):83-9
 Abstract

 

Nelfinavir
 

     Journal Papers, Abstracts, and Commentaries

  A WEEK-IN-REVIEW FEATURED REPORT
 Clinical evaluation of the nelfinavir-rifabutin interaction in patients with tuberculosis and
human immunodeficiency virus infection.
 Benator DA, Weiner MH, Burman WJ, et al
Pharmacotherapy. 2007 Jun;27(6):793-800.
Abstract
Pegylated IFN-alpha2a
 

     Journal Papers, Abstracts, and Commentaries

  Safety and Tolerability of Sequential Pegylated IFN-alpha2a and Tenofovir for Hepatitis B
Infection in HIV+ Individuals.
Johnson; Ristig; Overton; et al
HIV Clin Trials. 2007 May-Jun;8(3):173-81.
Abstract
Rilpivirine
 
     Journal Papers, Abstracts, and Commentaries
 
  Efficacy and safety of rilpivirine in treatment-naive, HIV-1-infected patients with hepatitis B virus/
hepatitis C virus coinfection enrolled in the Phase III randomized, double-blind ECHO and THRIVE trials.
Nelson M, Amaya G, Clumeck N, et al
 J Antimicrob Chemother. 2012 Apr 23
 Abstract
Sorafenib
 

     Journal Papers, Abstracts, and Commentaries

  Complete response after sorafenib therapy for hepatocellular carcinoma in an HIV-HBV co infected patient:
Possible synergy with HAART ? A case report.
Chelis L, Ntinos N, Souftas V,  et al
Med Oncol. 2011 Dec;28 Suppl 1:165-8.
Abstract

Complete response after sorafenib therapy for hepatocellular carcinoma in an
HIV-HBV co infected patient: Possible synergy with HAART ? A case report.
 Chelis L, Ntinos N, Souftas V,  et al
Med Oncol. 2010 Aug 31.
Abstract
Raltegravir
 

     Conference Reports, Abstracts, and Posters

  POSTER
 Hepatic Safety and Efficacy of Raltegravir in Patients Co-infected with HIV and HBV or HCV
 J Rockstroh, H Teppler, J Zhao, et al
(17th CROI)
PDF Poster     Abstract
Antiretrovirals: General Reports
 

     Journal Papers, Abstracts, and Commentaries

 
Hepatitis B and long-term HIV outcomes in coinfected HAART recipients.
 Hoffmann CJ, Seaberg EC, Young S, et ala
AIDS. 2009 Jun 22
 Abstract
 

Antiviral Combination Therapy for Treatment of Chronic Hepatitis B, Hepatitis C,
and Human Immunodeficiency Virus Infection.
 Hofmann WP, Soriano V, Zeuzem S.
Handb Exp Pharmacol. 2009;189:321-346.
 Abstract
 
Impact of hepatitis B virus co-infection on response to highly active antiretroviral treatment
and outcome in HIV-infected individuals: a nationwide cohort study.
 Omland LH, Weis N, Skinhøj P, et al 1:
HIV Med. 2008 May;9(5):300-6.
 Abstract
 
Major causes of antiviral drug resistance and implications for treatment of hepatitis B virus
monoinfection and coinfection with HIV.
Locarnini S, Warner N. 
Antivir Ther. 2007;12 Suppl 3:H15-23.
 Abstract
 
Comparison of first antiretroviral treatment duration and outcome in HIV, HIV-HBV and
HIV-HCV infection.
 Cooper CL, Mills E.
Int J STD AIDS. 2007 Aug;18(8):546-50.
 Abstract
 
Impact of Highly Active Antiretroviral Therapy (HAART) on the Natural History of Hepatitis
B Virus (HBV) and HIV Coinfection: Relationship between Prolonged Efficacy of HAART
and HBV Surface and Early Antigen Seroconversion.
Miailhes P, Trabaud MA, Pradat P, et al
Clin Infect Dis. 2007 Sep 1;45(5):624-32.
 Abstract
 
Virological Outcome of Chronic Hepatitis B Virus Infection in HIV-Coinfected Patients
Receiving Anti-HBV Active Antiretroviral Therapy.
Nunez M, Ramos B, Diaz-Pollan B, et al
AIDS Res Hum Retroviruses. 2006 Sep;22(9):842-8.
 Abstract

Antiretroviral Therapy for Hepatitis B Virus-HIV-Coinfected Patients: Promises and Pitfalls.
Levy V, Grant RM.
Clin Infect Dis. 2006 Oct 1;43(7):904-10.
Abstract
 
     Conference Reports, Abstracts, and Posters
 
 
Immunopathogenesis of Hepatic Flares after Initiation of ART in HIV/HBV-co-infected Individuals
 M Crane, B Oliver, G Matthews, et al
 (15 CROI)
Abstract
 
Evolution of Hepatitis B Virus Serological Markers in HIV-infected Persons Receiving
HAART
WH Sheng, C-C Hung, SC Chang
(14 CROI)
Abstract
 
Occult Hepatitis B Viremia in HIV-infected Individuals on 3TC-containing ART and Its
Relationshipto Immunologic Status
D Bhattacharya, D Katzenstein, D Israelski, et al
(14 CROI)
Abstract

POSTER
 Risk Factors for Liver Enzymes Elevation in HIV/HBV-co-Infected Patients: Impact of ART
 O Chauvel, K Lacombe,  G Pialoux, et al
(14 CROI)
 PDF Poster    Abstract
 

HIV/HBV Main Page Main New/Newsworthy  Home Page

HIV/HBV Drugs